CLINICAL TRIALS PROFILE FOR ACARBOSE
✉ Email this page to a colleague
All Clinical Trials for acarbose
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000620 ↗ | Action to Control Cardiovascular Risk in Diabetes (ACCORD) | Completed | Centers for Disease Control and Prevention | Phase 3 | 1999-09-01 | The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management. |
| NCT00000620 ↗ | Action to Control Cardiovascular Risk in Diabetes (ACCORD) | Completed | National Eye Institute (NEI) | Phase 3 | 1999-09-01 | The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management. |
| NCT00000620 ↗ | Action to Control Cardiovascular Risk in Diabetes (ACCORD) | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 3 | 1999-09-01 | The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management. |
| NCT00000620 ↗ | Action to Control Cardiovascular Risk in Diabetes (ACCORD) | Completed | National Institute on Aging (NIA) | Phase 3 | 1999-09-01 | The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management. |
| NCT00000620 ↗ | Action to Control Cardiovascular Risk in Diabetes (ACCORD) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1999-09-01 | The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and multiple lipid management. |
| NCT00032487 ↗ | Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) | Completed | National Eye Institute (NEI) | Phase 3 | 2000-12-01 | This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications. |
| NCT00032487 ↗ | Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) | Completed | SmithKline Beecham | Phase 3 | 2000-12-01 | This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for acarbose
Condition Name
Clinical Trial Locations for acarbose
Trials by Country
Clinical Trial Progress for acarbose
Clinical Trial Phase
Clinical Trial Sponsors for acarbose
Sponsor Name
